Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

Synthetic

ADB-FUBINACA

An indazole-3-carboxamide agonist at CB1 and CB2; in Schedule II of the 1971 Convention since 2019, a narcotic in France.

Narcotic: named in schedule
Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₁H₂₃FN₄O₂

CAS 1445583-51-6

Family
Synthetic CB receptor agonistNew psychoactive substance
Molar mass
382.40 g/mol

Updated on

In plain terms

ADB-FUBINACA is a synthetic cannabinoid of the indazole-3-carboxamide family, close to compounds described in a 2009 Pfizer patent. It activates CB1 and CB2 receptors. It is a narcotic in France and has been in Schedule II of the 1971 Convention since 2019.

Receptors and activity

Target network

CB1Agonistno measured value
  • Activates

The lower the cited value, the closer the target sits to ADB-FUBINACA: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of ADB-FUBINACA.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Map sources

  1. Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
  2. Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
  3. Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
  4. Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)

Cited values

  1. CB1Agonistno measured value cited
  2. CB2Agonistno measured value cited
Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

ADB-FUBINACA is an indazole-3-carboxamide: an indazole ring substituted on the nitrogen by a 4-fluorobenzyl group and, at position 3, by a carboxamide linked to a tert-leucine amide. This family is described in the Pfizer patent WO 2009/106980 (priority of 29 February 2008, published 3 September 2009), devoted to CB1 agonists. Banister et al. (2015) synthesised and tested it together with AB-FUBINACA, AB-PINACA, ADB-PINACA and other compounds: all acted as high-potency agonists at CB1 (EC50 of 0.24 to 21 nM) and CB2 (EC50 of 0.88 to 15 nM) receptors. It has been in Schedule II of the 1971 Convention since CND decision 62/5 (19 March 2019) and is in Annex III of the French list of narcotics.

Key sources.

History

Source
Designer-drug market; family of indazole-3-carboxamides described in a Pfizer patent (WO 2009/106980)

Origin

Laboratory synthesis

Indazole-3-carboxamide: an indazole substituted on the nitrogen by a 4-fluorobenzyl group and, at position 3, by a carboxamide linked to an L-tert-leucine amide

Classification

Family, origin and source verification

Family

Synthetic CB receptor agonist › New psychoactive substance

Class

indazole-3-carboxamide

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

ADB-FUBINACA (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

  1. Banister · ACS Chem Neurosci 2015 (new tab)PMID 26134475

Identifiers

Names

IUPAC name
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-[(4-fluorophenyl)methyl]indazole-3-carboxamide

Identifiers

Formula
C₂₁H₂₃FN₄O₂
CAS
1445583-51-6
PubChem CID
70969086(new tab)
InChIKey
ZSSGCSINPVBLQD-UHFFFAOYSA-N
SMILES
CC(C)(C)C(C(=O)N)NC(=O)C1=NN(C2=CC=CC=C21)CC3=CC=C(C=C3)F

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.